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Abstract
Introduction: Obesity is associated with low-grade systemic inflammation. The ‘‘inflammome’’ is a network layout of the
inflammatory pattern. The systemic inflammome of obesity has not been described as yet. We hypothesized that it can be
significantly worsened by smoking and other comorbidities frequently associated with obesity, and ameliorated by bariatric
surgery (BS). Besides, whether or not these changes are mirrored in the lungs is unknown, but obesity is often associated
with pulmonary inflammation and bronchial hyperresponsiveness.
Objectives: We sought to: (1) describe the systemic inflammome of morbid obesity; (2) investigate the effects of sex,
smoking, sleep apnea syndrome, metabolic syndrome and BS upon this systemic inflammome; and, (3) determine their
interplay with pulmonary inflammation.
Methods: We studied 129 morbidly obese patients (96 females; age 46612 years; body mass index [BMI], 4666 kg/m2)
before and one year after BS, and 20 healthy, never-smokers, (4367 years), with normal BMI and spirometry.
Results: Before BS, compared with controls, all obese subjects displayed a strong and coordinated (inflammome) systemic
inflammatory response (adiponectin, C-reactive protein, interleukin (IL)-8, IL-10, leptin, soluble tumor necrosis factor-
receptor 1(sTNF-R1), and 8-isoprostane). This inflammome was not modified by sex, smoking, or coexistence of obstructive
sleep apnea and/or metabolic syndrome. By contrast, it was significantly ameliorated, albeit not completely abolished, after
BS. Finally, obese subjects had evidence of pulmonary inflammation (exhaled condensate) that also decreased after BS.
Conclusions: The systemic inflammome of morbid obesity is independent of sex, smoking status and/or comorbidities, it is
significantly reduced by BS and mirrored in the lungs.
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Introduction
Obesity is a major and raising global health problem. Among
others, it increases significantly the risk of cardiovascular disease
and premature death [1]. A key mechanism explaining this
association appears to be the release by adipocytes of the so-called
adipokines, such as leptin and adiponectin [2], a family of
mediators that influences body weight homeostasis, insulin
resistance and inflammation, and eventually causes endothelial
dysfunction and atherosclerosis [3]. In addition, external risk
factors such as smoking often contribute to enhance the adverse
effects of obesity on cardiovascular health [3].
Bariatric surgery (BS) results in significant and sustained weight
loss in morbidly obese subjects with minor morbidity or mortality
[4–6]. Previous studies indicate that systemic inflammation in
obese subjects appears to be reduced after BS [4;7]. Notwith-
standing, the inflammatory response is complex and includes the
contribution of many different cells and mediators [8]. Network
analysis allows a more comprehensive approach to complex
biological systems [9] with the potential of unraveling novel
interplays among apparently disconnected mediators and clinical
manifestations [10;11]. This research strategy has already proved
to be useful to dissect the biological and environmental
determinants of obesity [12] and smoking [13], as well as to
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e107859
characterize the systemic inflammatory pattern (so-called, inflam-
mome) associated with smoking and chronic obstructive pulmo-
nary disease (COPD) [8]. In this study we describe for the first
time the inflammome of morbid obese individuals and test the
hypothesis that it could be significantly worsened by smoking or
other comorbidities frequently associated to severe obesity, such as
the obstructive sleep apnea syndrome (OSAS) and the metabolic
syndrome (MS) and be ameliorated after BS. Besides, given that
obesity is often associated with pulmonary inflammation and
bronchial hyperresponsiveness [14–16], we also sought to inves-
tigate potential relationships between systemic and pulmonary
inflammation in the morbid obese, so that we also quantified a
number of inflammatory markers in the exhaled gas condensate in
morbid obese, both before and after BS.
Methods
For more information see Methods S1.
Study Design, Participants and Ethics
This was a prospective, observational study in which we
enrolled: (1) 129 obese individuals (96 females/33 males; age
46612 years) with a body mass index (BMI) $40 kg/m2 (or $
35 kg/m2 in those with comorbidities) without major cardiovas-
cular and chronic obstructive airway diseases, candidates to BS;
and, (2) 20 healthy, normal weighted, sex- (16 females/4 males)
and age-matched (4367 years) non-smokers with normal spirom-
etry, who served as controls. Obese participants were studied
before (mean, 864 weeks; median, 5 weeks) and one year (1564
months; median, 13 months) after BS. The project was approved
by the Ethics Committee for Clinical Research (Comite` E`tic
d’Investigacio´ Clı´nica) of Hospital Clı´nic of Barcelona (2008/
4015) and all participants signed their written informed consent.
Measurements
The following measurements were obtained in all obese subjects
before and after BS. Forced spirometry, plethysmographic lung
volumes, arterial blood gases and the 6-minute walking test
(6MWT) were determined according to international recommen-
dations [17–19]. Reference values were those of Roca et al. [20–
22]. An apnea/hypopnea index (AHI) $15 events/h was
considered indicative of OSAS [23].
Serum was obtained after overnight fasting by peripheral
venopuncture followed by centrifugation and stored at 280uC
until analysis. The serum concentration of adiponectin, C-reactive
protein (CRP), interleukin (IL)-8, IL-10, leptin, soluble tumor
necrosis factor-receptor 1(sTNF-R1), and 8-isoprostane were
determined, as previously reported [24]. The serum concentration
of C-reactive protein (CRP) were determined using an immuno-
turbidimetry method (Advia Chemistry, Siemens Tarrytown, NY,
USA) and those of leptin (Diagnostic Biochem Canada Inc.
Ontario, Canada), serum adiponectin, soluble tumor necrosis
factor-receptor 1(sTNF-R1), interleukin (IL)-8, IL-10 and 8-
isoprostane by ELISA (US Biological Salem, MA, USA; IBL
international Hamburg, Germany; ANOGEN Ontario, Canada
and Cayman Chemical Company, Ann Arbor, MI, US, respec-
tively). All biomarkers were quantified in duplicate and their mean
values were used for analysis. In some individuals serum
biomarker concentrations were below the lower limit of quanti-
fication (LLQ). To avoid a downward bias of biomarkers, a
nominal level of half of the LLQ value was used in the analysis in
individuals with values below the LLQ [25]. Exhaled breath
condensate samples were obtained using an EcoScreen condenser
(Jaeger, Wu¨rzburg, Germany) following international recommen-
dations [26;27] and the concentrations of IL-8, IL-10 and 8-
isoprostane were measured by ELISA (Cayman Chemical
Company, Ann Arbor, MI, US).
Forced spirometry and serum and exhaled biomarker concen-
trations were determined in control participants only once.
Statistical Analysis
Results are described as mean 6 standard deviation (SD),
median [interquartile range] [IQR] or absolute and relative
frequencies (%), as appropriate. Quantitative variables, were tested
for normality using a Kolgomorov-Smirnov test and parametric
(paired and unpaired t-test) and non-parametric (Wilcoxon and
Mann-Whitney tests) were used accordingly to compare quanti-
tative variables between patients and controls (at baseline) and
between patients before and after BS. Fisher’s exact test and
McNemar test were used for qualitative variables.
As described previously [8], we used the 95th (and 5th) percentile
value determined in controls as the upper (and lower) normal
levels, so biomarker concentrations beyond these threshold were
considered abnormal in obese subjects. Cross tabulations between
healthy and obese subjects, before and after BS and also in
different subsets of obese individuals according to sex, smoking
status and coexistence of OSAS and MS, were determined to
analyze biomarker alterations and their interactions. All statistical
tests were two-sided and a p value ,0.05 was considered
significant. Due to the observational characteristics of this study
p values presented were nominal and not adjusted for multiplicity.
Data analysis was carried out with SPSS 20.0 (IBM Corporation).
Results
Characterization of Participants
Table 1 presents the main demographic and clinical character-
istics of participants. BMI, waist and waist-to-hip ratio were, as
compared to control, higher in obese subjects, but age and
proportion of females were similar in the two populations. Only 21
obese subjects were current smokers ($10 pack-years). Most obese
subjects were non- (,10 pack-years) or former (.1 year after
cessation) smokers, and their level of dyspnea was mild-to-
moderate. Comorbidities were common in obese individuals,
especially OSAS (67%) and MS (78%). As shown in Table 2
obese, as compared to control participants, had reduced forced
spirometric and pulseoximetry values, although within normal
limits, along with diminished expiratory reserve volume (ERV)
and functional residual capacity (FRC) values. Mean PaO2 (range,
57-119 mmHg) was within normal limits and mean alveolar-
arterial PO2 difference (AaPO2) was abnormally enlarged (range,
0–51 mmHg). The former two values were more abnormal in
males than in females (Tables S1 and S2).
Systemic Inflammation
The mean concentration of most serum inflammatory biomark-
ers was significantly higher in obese than in control subjects,
except for adiponectin, which was lower (Table 2). Figure 1
presents the frequency distribution of the number of abnormal
serum biomarker values in obese individuals (.95th percentile of
controls (or ,5th percentile in the case of adiponectin) [8]. Not a
single obese subject had a normal battery of biomarkers and the
majority exhibited at least 5 or more abnormal biomarkers. We
observed that BMI was significantly associated to the serum
concentrations of CRP (Rho, 0.31; p,0.001) and leptin (Rho,
0.41; p,0.001) values, whereas descriptors of central adiposity, i.e.
waist circumference, were associated to sTNF-R1 (Rho, 0.25; p,
0.01) and adiponectin (Rho, -0.18; p,0.05) levels.
Obesity & Systemic Inflammation
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The systemic inflammome is a network representation (Fig-
ure 2) of the prevalence and relationships between the different
inflammatory markers determined in serum [8;28]. In obese
subjects, all nodes were significantly larger than in control
participants (indicating a higher prevalence of abnormal values)
and there were many significant interactions among the different
inflammatory biomarkers determined (Figure 2). By contrast, in
control subjects, nodes were by definition small, many of them
were not linked to the others and, in any case, links were few and
thin, indicating the virtual absence of systemic inflammation.
We explored the effects of a number of factors that can
potentially influence the systemic inflammome of morbid obesity,
including sex, smoking status, and coexistence of OSAS or MS
[24;29–31]. By and large, differences between males and females
(Figure S1), current or former and non-smokers (Figure S2), and/
or participants with or without OSAS and/or MS (Figures S3 and
S4, respectively) were modest or absent, indicating that morbid
obesity by itself was the main driving force of the systemic
inflammome in these patients. Nevertheless, some (small) changes
deserve comment.
Pulmonary Inflammation
A large proportion of obese subjects had abnormal levels (.95th
percentile of controls) of exhaled IL-8 (56%) and IL-10 (15%) so
that their mean values were significantly higher in obese subjects
(Table 2). On the other hand, albeit exhaled 8-isoprostane was
within the normal range in all obese individuals, mean values were
significantly lower (Table 2). We did not observe significant
differences in any of these exhaled inflammatory markers
according to sex, smoking status and/or presence of OSAS and/
or MS. The AHI and the concentration of exhaled breath
biomarkers were not significantly related. By contrast, we observed
a positive correlation between the concentration of exhaled IL-8
and serum sTNF-R1 (Rho, 0.24; p,0.01) and between exhaled
IL-8 and serum 8-isoprostane (Rho, 0.27; p,0.01) as well.
Findings One Year after Bariatric Surgery
Sleeve gastrectomy was performed in 68 (53%) and Roux-en-Y
gastric bypass in 61 (47%) obese subjects. Ninety-one percent of
obese subjects (n = 118) had an excess weight loss.50%
(75618%), a marker of BS success [4].
Tables 1 and 2 show that most clinical and functional outcomes
improved and most inflammatory markers were reduced after BS.
All lung function tests improved significantly after BS but it should
be noted that they were already within normal limits before
surgery. It is of note that the 6MWT substantially increased and
this was a novel post-operative finding in morbid obese.
The effects of BS upon systemic inflammation are illustrated in
Figures 1 and 2. There was a dramatic downward shift of the
frequency distribution of obese subjects with abnormal biomarkers
with a marked shrinking of the systemic inflammome after BS,
both in terms of node size and link width. Of note, however, that
some patients still remained inflamed after BS (Figures 1 and 2).
Finally, we observed that the exhaled concentrations of IL-8 and
IL-10 (but not those of 8-isoprostane) were also significantly
reduced after BS (Table 2).
Discussion
This study describes, for the first time to our knowledge, the
systemic inflammome associated with morbid obesity and shows
that it is: (1) barely modified by sex, smoking status and/or
Table 1. Main demographic and clinical characteristics of control and obese participants (mean 6 SD or n (%)).
CONTROL SUBJECTS OBESE SUBJECTS
P Value * BEFORE BS P Value { AFTER BS
Demographics
Age, years 4367 0.7 46612 0.68 47612
Female,% 83 0.24 74 --- 74
Body mass index, kg/m2 2263 ,.001 4666 ,.001 3065
Waist circumference, cm 8068 ,.001 130614 ,.001 99613
Waist-to-hip ratio 0.8460.09 0.001 0.9360.09 0.016 0.8960.09
Clinical features
Non-Smokers, n (%) 20 ,.001 75 (58) ,.001 75 (58)
Current smokers, n (%) 0 ,.001 21 (16) .08 17 (13)
Tobacco, pack-years 0 ,.001 34632 .36 35632
Ex-smokers, n (%) 0 ,.001 33 (26) .43 37 (29)
Tobacco, pack-years 0 ,.001 35624 .97 35624
Dyspnea level (mMRC) 0 ,.001 1.260.8 ,.001 0.160.3
Obstructive Sleep Apnea, n (%) — NA 87 (67) ,.001 13 (10)
Apnea Hypopnea Index, events/h — NA 60634 ,.001 17615
Metabolic Syndrome, n (%) 0 ,.001 100 (78) ,.001 20 (16)
Diabetes Mellitus type 2, n (%) 0 ,.001 52 (40) ,.001 12 (9)
Hypertension, n (%) 0 ,.001 77 (60) ,.001 37 (29)
Demographic and clinical characteristics of healthy and obese individuals, before and after bariatric surgery. NA: not applicable; * p-values for comparisons between
controls individuals and obese subjects before bariatric surgery whereas { indicate p-values for comparisons between obese subjects before and after bariatric surgery.
doi:10.1371/journal.pone.0107859.t001
Obesity & Systemic Inflammation
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coexistence of OSAS and/or MS; (2) significantly reduced, albeit
not fully normalized, after BS; and, (3) related to pulmonary
inflammation.
Previous Studies
Several previous studies have shown that severe obesity is
associated with systemic inflammation that is considerably reduced
after BS [4;7]. Our findings confirm and expand these previous
results by providing an integrated network approach of the
interplay among the different inflammatory markers (inflammome)
as well as the effects of potential confounders, such as sex,
smoking, OSAS and/or MS, and BS. This approach has been
used successfully in other diseases, such as COPD [8;32]. On the
other hand, it is also worth noting that many previous papers have
also investigated the effects of obesity on lung function [14–16;33],
including a recent report by our group that used the multiple inert
gases elimination technique (MIGET) to investigate the pulmo-
nary and non-pulmonary factors governing gas exchange in a
small subset of females [24].
Interpretation of Findings
Several observations of our study deserve specific discussion.
First, our results confirm [3;34–35] that morbid obesity is
associated with a notable systemic inflammation component
(Figure 1), here illustrated for the first time as an inflammome
(Figure 2). Adipose tissue is an active endocrine organ capable of
producing cytokines and hormones that regulate metabolism and
immune responses [36]. Hotamisligil et al. coined the term ‘‘meta-
inflammation’’ (metabolically triggered inflammation) to describe a
condition triggered by nutrients that engages a similar set of
Table 2. Lung function and inflammatory markers in control and obese participants, before and after bariatric surgery (mean6 SD
or median [interquartile range]).
CONTROL SUBJECTS OBESE PATIENS
P Value * BEFORE BS P Value { AFTER BS
Lung function
FVC,% pred 103613 0.003 91613 ,.001 103613
FEV1,% pred 102613 0.02 94615 ,.001 104614
FEV1/FVC,% 7164 0.008 8265 ,.001 7969
FRC,% pred ND --- 73613 ,.001 113625
ERV,% pred ND --- 34623 ,.001 106636
TLC,% pred ND --- 92610 ,.001 106613
RV/TLC,% ND --- 3567 0.14 3668
SGaw, s-1?cmH2O-1 ND --- 0.1160.04 0.002 0.1360.10
PaO2, mmHg ND --- 82612 ,.001 93611
PaCO2, mmHg ND --- 3764 ,.001 3965
AaPO2, mmHg ND --- 23610 ,.001 9611
SaO2,% 9861 0.046 9763 0.36 9767
6MWT, m ND --- 471675 ,.001 546676
Serum markers
Leucocytes, 109/l 6,215 [5490–7682] ,.001 8,010 [6,825–9,395] ,.001 6,700 [5,600–7,855]
C-Reactive Protein, mg/l 0.40 [0.16–0.70] ,.001 7.80 [4.30–14.50] ,.001 0.60 [0.20–1.45]
Fibrinogen, mg/dl 320 [280–350] ,.001 420 [368–480] ,.001 370 [333–438]
Leptin, ng/ml 13.60 [5.66–18.93] ,.001 63.00 [42.85–101.35] ,.001 15.00 [6.70–28.85]
Adiponectin, mg/ml 22.66 [18.70–25.92] ,.001 9.58 [4.88–15.85] ,.001 17.12 [9.68–22.55]
sTNF-R1, ng/ml 0.24 [0.07–0.43] ,.001 1.50 [1.01–2.24] ,.001 0.89 [0.34–1.61]
IL-8, pg/ml 4.00 [4.00–5.56] 0.019 9.22 [4.00–25.02] 0.012 4.00 [0.98–13.66]
IL-10, pg/ml 3.50 [3.50–148.54] 0.72 3.50 [3.50–16.59] 0.46 3.50 [3.50–11.45]
8-isoprostane, pg/ml 40.24 [23.90–58.50] ,.001 162.25 [108.30–211.90] 0.26 163.30 [93.27–213.36]
Exhaled condensate markers
Exhaled IL-8, pg/ml 0.60 [0.33–1.36] ,.001 4.77 [2.21–8.74] 0.019 3.83 [1.26–6.79]
Exhaled IL-10, pg/ml 4.71 [2.32–7.46] ,.013 8.84 [4.75–15.24] 0.004 6.13 [4.07–10.29]
Exhaled 8-isoprostane, pg/ml 350.91 [177.31–603.23] 0.018 231.80 [113.15–362.69] 0.86 216.00 [129.65–372.65]
ND: Not done; FRC: functional residual capacity; ERV: expiratory reserve volume; TLC: total lung capacity; RV: residual volume; SGaw: specific conductance; 6MWT: 6-
minute walking test; sTNF-R1: soluble tumor necrosis factor-receptor 1; IL: interleukin. * p-values for comparisons between controls individuals and obese subjects
before bariatric surgery whereas { indicate p-values for comparisons between obese subjects before and after bariatric surgery.
doi:10.1371/journal.pone.0107859.t002
Obesity & Systemic Inflammation
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molecules and signaling pathways to those involved in other, more
classical, forms of inflammation [37]. It is also known that, in
obesity, the hypertrophic adipose tissue becomes infiltrated with
pro-inflammatory macrophages, produces more pro-inflammatory
cytokines and less adiponectin (an anti-inflammatory adipokine)
and contributes to the systemic complications of obesity, including
diabetes type 2 and MS, as well as to increased cardiovascular risk
in these populations [37–38].
Second, contrary to our working hypothesis, we were not able to
identify a clear effect of sex, smoking, OSAS or MS upon the
systemic inflammome of morbidly obese individuals (Figures S1–
S4), indicating that obesity per se is likely the main driving force of
systemic inflammation in this clinical setting. By contrast, we
observed a very significant effect of BS (Figure 2). Our findings
confirm that BS is a safe and effective option for the treatment of
very severe obesity but also showed that it has a profound effect on
the systemic inflammome of these individuals (Figures 1 and 2).
This may be related to the reduction of macrophage infiltration of
adipose tissue, as well as to the change in the pro-inflammatory
macrophage phenotype that has been reported after weight loss
[39]. This further supports a key role of obesity in the
pathobiology of systemic inflammation in these patients.
Finally, an important novel observation of our study relates to
pulmonary inflammation in morbid obesity. In keeping with
previous studies [30–31;40], we found evidence of airway
inflammation in obese subjects (Table 2), but our results extend
and complement these previous reports by showing that there was
a significant interplay between systemic and pulmonary biomark-
ers and, notably, that BS not only reduced systemic inflammation
but had a similar anti-inflammatory effect in the lungs as well.
Most previous studies of pulmonary inflammation in obese
subjects included individuals with OSAS [30–31;40–42], which
was in fact believed to be the main pathogenic driver of the
observed pulmonary inflammation. In contrast, we observed that
airway inflammation was not different in obese patients with or
without OSAS (and/or MS, or smoking). In keeping with these
observations, a recent study in adults with obesity and OSAS has
shown that the combined use of CPAP and weight-loss did not
reduce serum CRP levels more than either intervention alone [43].
The fact that pulmonary inflammation was significantly reduced
after BS in our study further supports the key role played by
obesity in the pathogenesis of both systemic and pulmonary
inflammation. In closing, exhaled 8-isoprostane, derived from free
radical-catalyzed peroxidation of arachidonic acid, is a reliable
biomarker of oxidative stress [44–45]. Pre-operative exhaled
breath condensate levels of 8-isoprostane in obese patients were
lower than in control participants (Table 2), suggesting that either
oxidative stress does not play a key role in airway inflammation of
morbidly obese subjects and/or that these individuals have
developed a more efficient anti-oxidant capacity.
Strengths and Limitations
Our study has both strengths and limitations. As alluded to this
is the first study to use a more comprehensive network approach to
investigate the inflammatory pattern associated with morbid
obesity, as well as the effects of potential confounding factors
and BS, both in the systemic and pulmonary compartments. We
acknowledge that we quantified a relatively low number of
biomarkers and that we did not measure their levels in adipose or
lung tissue.
Conclusion
Morbid obesity is associated with a significant systemic
inflammome that is not influenced by sex, smoking status,
presence of obstructive sleep apnea and/or metabolic syndrome,
is related to pulmonary inflammation, and is significantly
ameliorated after bariatric surgery.
Figure 1. Frequency distribution of obese individuals according to the number of abnormal systemic (serum) biomarker values
(.95th percentile of controls (or ,5th percentile in the case of adiponectin), before and after BS.
doi:10.1371/journal.pone.0107859.g001
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Supporting Information
Figure S1 Systemic inflammome in obese participants
classified according to sex before BS (for further
explanation, see legend to Figure 2).
(TIF)
Figure S2 Systemic inflammome in obese participants
classified according to smoking habits before BS. Current
smokers ($10 pack-years); non- (,10 pack-years) or former (.1
year after cessation) smokers (for further explanation, see legend to
Figure 2).
(TIF)
Figure S3 Systemic inflammome in obese participants
classified according to the presence or absence of
obstructive sleep apnea syndrome (OSAS) before BS.
OSAS was define as apnea/hypopnea index.15 events/hour (for
further explanation, see legend of Figure 2).
(TIF)
Figure S4 Systemic inflammome in obese participants
classified according to the presence or absence of
metabolic syndrome (MS) before BS (for further expla-
nation, see legend to Figure 2).
(TIF)
Table S1 Demographic and clinical characteristics
(mean ± SD or median [interquartile range]).
(DOC)
Table S2 Functional characteristics and serum and
Exhaled Breath Condensate Biomarkers in Obese
Individuals divided according to sex.
(DOC)
Methods S1 Additional information regarding methods.
(DOC)
Acknowledgments
The authors thank the participants in the study for their willingness to
contribute to medical research, and Maribel Diaz, PhD, Yolanda Torralba,
MsC, Conchi Gistau, RT, and Conchita Ruiz, RT, Patricia Molina, RT,
Marc Pino, RT (all at Hospital Clı´nic), and Mo´nica Vila`-Ubach, RT
(Hospital del Mar) for their skillful technical help.
Author Contributions
Conceived and designed the experiments: RRR JV AA EA. Performed the
experiments: EA ER EB. Analyzed the data: EA AA RRR JV JR.
Contributed reagents/materials/analysis tools: EA AA RRR JV JR EB.
Wrote the paper: EA AA RRR.
Figure 2. Systemic inflammome in healthy and obese individuals before and after BS. Each node represents one inflammatory marker and
color indicates the type of inflammatory marker considered (acute phase reactants, cytokines, adipokines or oxidative stress). The node diameter is
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